Global Phosphate Binder (Hyperphosphatemia) Market: Industry Analysis & Outlook (2019-2023)

Phosphate binder also referred as phosphorus binder, is a medication prescribed to reduce the absorption of dietary phosphate and to control the amount of phosphorus in the blood. They are frequently used by people with chronic kidney failure, who are not able to excrete phosphate and causing a high level of phosphate level in the body. Phosphate binders bind phosphate and are then excreted from the body.

Phosphate binders such as aluminum-based antacids, magnesium-based antacids, calcium carbonate, calcium acetate, sevelamer, and lanthanum are essential for patients whose phosphorus levels stay high despite dietary restrictions. Controlling phosphate level is important as it is associated with bone pathology and accompanied with elevated calcium level by the parathyroid hormone.

The global phosphate binder market is driven by an increasing aging population as well as the rising prevalence of chronic kidney diseases. The drugs, namely Velphoro, Auryxia, PhosLo, and Renegal are expected to show high growth prospects in the coming years. Since a large part of the population suffers from kidney diseases, the chances of developing end-stage renal failure have increased to a large extent, thereby propelling the growth of the market during the forecasted period.

With the advancements in the healthcare infrastructure in the U.S., the phosphate binder medication growth is estimated to continue and thereby, making this region a potential opportunity for manufacturers. The number of treated population is also rising owing to increase in awareness regarding treatment.

The report “Global Phosphate Binder Market: Industry Analysis & Outlook (2019-2023)” provides extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the United States, Europe, and Japan regions along with the global market. The report profiles the key players of the market including AMAG Pharmaceuticals, Inc., Vifor Pharma Ltd., Sanofi S.A., and Akebia Therapeutics Inc.

Please note: 10% free customization equates to up to 3 hours of analyst time.

1. Market Overview

1.1 Chronic Kidney Disease (CKD)
1.2 Hyperphosphatemia
1.3 Phosphate Binder
1.4 Phosphate Binder Products

2. Global Phosphate Binder Market

2.1 Global Phosphate Binders Drugs in Development
2.2 Global Phosphate Binder Prescription Market Share
2.3 Global Sevelamer Revenue
2.4 Global Sevelamer Prescription Market Share by Brand
2.5 Auryxia Prescription and Tablets Count
2.6 Global Velphora Revenue Forecast

3. Regional Markets

3.1 The U.S.
3.1.1 The U.S. Dialysis Patients on Phosphate Binder Forecast
3.1.2 The U.S. Peritoneal Dialysis Patients on Phosphate Binder Forecast
3.1.3 The U.S. Auryxia Revenue and Penetration Forecast
3.1.4 The U.S. Velphoro Revenue Forecast
3.2 Europe
3.2.1 Europe Phosphate Binder Treated Population Forecast
3.2.2 Europe Velphoro Revenue Forecast
3.3 Japan
3.3.1 Japan Phosphate Binder Treated Population Forecast
3.3.2 Japan Velphoro Revenue Forecast

4. Market Dynamics

4.1 Growth Drivers
4.1.1 Rising Aging Population
4.1.2 Increasing Healthcare Spending
4.1.3 Increasing Cases of ESRD
4.1.4 Increasing Life Expectancy
4.1.5 High Unmet Medical Needs
4.2 Key Trends & Developments
4.2.1 Increasing Demand for Effective Phosphate Binder Treatment
4.3 Challenges
4.3.1 Gastrointestinal Reactions Leading to Discontinuation
4.3.2 Entry of Generic Products
4.3.3 Regulatory Framework

5. Competitive Landscape

5.1 Global Market
5.1.1 Revenue and Market Cap Comparison
5.1.2 Research & Development Expenditure (as a % of Revenue) Comparison
5.1.3 Approved Phosphate Binders Dosage Comparison
5.1.4 Approved Phosphate Binders Safety Comparison
5.1.5 Approved Phosphate Binders Shortcomings Comparison

6. Company Profiles

6.1 AMAG Pharmaceuticals, Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Vifor Pharma Ltd.
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Sanofi S.A.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Akebia Therapeutics Inc.
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies

List of Figures